5 Medicare Drug Changes for 2026 That Caught Experts by Surprise

The Inflation Reduction Act of 2022 set in motion some of the most significant changes to Medicare in decades, particularly regarding prescription drug costs. While some updates were anticipated, several specific provisions have left policy experts and industry analysts dissecting the long-term implications. Here is a clear breakdown of five changes for 2026 that challenged previous assumptions.

1. The Aggressive List of Drugs for First-Round Price Negotiations

For years, the idea of Medicare directly negotiating drug prices was a major policy goal, but its actual implementation was a source of debate. When the Centers for Medicare & Medicaid Services (CMS) announced the first 10 Part D drugs selected for negotiation, the specific choices and their combined market impact were striking.

Experts were surprised by the list’s focus on widely used, blockbuster medications that form the bedrock of treatment for millions of seniors. The list included:

• Eliquis and Xarelto: Two leading blood thinners.
• Jardiance, Januvia, and Farxiga: Popular diabetes medications.
• Entresto: A cornerstone heart failure treatment.
• Enbrel: A widely used biologic for autoimmune conditions.
• Imbruvica: A key cancer treatment.
• Stelara: A medication for psoriasis and Crohn’s disease.
• Fiasp and NovoLog insulin products: Essential for diabetes management.

The surprise was not just that Medicare would negotiate, but that it would start with such high-impact, high-spend drugs right out of the gate. Many analysts had predicted a more cautious, phased-in approach beginning with less common or older medications. This aggressive first step signaled a firm commitment to tackling the largest drivers of prescription drug spending immediately, setting a powerful precedent for all future negotiations.

2. The Rigid "Maximum Fair Price" Formula

Another unexpected element was how the “negotiated” price would be determined. Instead of a traditional open-ended negotiation process, the Inflation Reduction Act established a very specific price ceiling called the “Maximum Fair Price” (MFP). This price is not a suggestion; it is the highest price Medicare will pay.

What caught experts off guard was the rigid, formulaic nature of this ceiling. The law dictates the minimum discount off a drug’s average non-federal price, and it depends entirely on how long the drug has been on the market:

• Short-Monopoly Drugs (9 to 12 years): A minimum 25% discount.
• Extended-Monopoly Drugs (12 to 16 years): A minimum 35% discount.
• Long-Monopoly Drugs (16+ years): A minimum 60% discount.

This prescriptive approach removes much of the ambiguity from negotiations. While manufacturers can present evidence to argue for a higher price (up to the ceiling), they cannot exceed it. Policy analysts were surprised by this lack of flexibility, as it transforms the process from a free-form negotiation into a structured pricing exercise with a hard cap. This ensures significant savings for Medicare but gives manufacturers much less room to maneuver than previously anticipated.

3. The Surprising "Orphan Drug" Negotiation Loophole

Orphan drugs, which treat rare diseases affecting fewer than 200,000 people in the U.S., have historically been shielded from pricing regulations to encourage pharmaceutical innovation in small markets. The Inflation Reduction Act maintains this general protection, exempting drugs that treat only one rare condition from price negotiation.

The surprise, however, was in the fine print. An orphan drug loses its exemption and becomes eligible for negotiation if it gains approval from the Food and Drug Administration (FDA) for a second indication, even if that new indication is not for a rare disease.

This created a significant and unexpected disincentive. A company might develop a successful drug for a rare cancer, for example. Later, they might discover it could also treat a more common condition like arthritis. Under the new law, seeking that second approval would put the drug’s price for all its uses on the negotiating table. Policy experts are still actively debating the unintended consequences of this rule, as it could discourage companies from researching valuable new uses for existing successful medications.

4. A Complete Overhaul of the Part D Benefit Structure

For years, policymakers have discussed capping out-of-pocket drug costs for Medicare beneficiaries, but the final design in the Inflation Reduction Act was a fundamental restructuring that surprised many. Starting in 2025, beneficiary out-of-pocket costs for Part D drugs will be capped at $2,000 per year.

While the cap itself is a major win for seniors, the surprising part is how the financial responsibility was redistributed. Previously, in the “catastrophic coverage” phase, Medicare paid 80% of drug costs, with plans paying 15% and beneficiaries 5%.

The new structure completely eliminates the catastrophic coverage phase and shifts the financial burden significantly:

• Medicare’s share drops dramatically: The government’s reinsurance portion falls from 80% in the old model to 20% for brand-name drugs and 40% for generics in the new model.
• Insurers pay more: Health plans’ responsibility increases substantially, as they will now cover 60% of costs for brand-name drugs after the beneficiary hits the cap.
• Manufacturers must contribute: For the first time, drug manufacturers are required to provide a 20% discount on brand-name drugs for beneficiaries who have exceeded their out-of-pocket maximum.

This wasn’t just a tweak; it was a complete redesign of the Part D financial model. Experts were surprised by the scale of this shift, which creates new incentives for insurers to manage high-cost drugs more aggressively and forces manufacturers to have a direct financial stake in the costs incurred by patients.

5. The Broad Power of the Inflation Rebate Penalty

The law also requires drug companies to pay rebates back to Medicare if they increase the price of their drugs faster than the rate of inflation. This provision applies to drugs covered under both Part D (pharmacy) and Part B (administered in a doctor’s office).

The surprising aspect was the immediate and retroactive power of this rule. The baseline for measuring price increases was set in 2021, meaning that any price hikes above inflation since then could trigger penalties. This forced manufacturers to immediately reassess their pricing strategies.

Furthermore, for Part B drugs, the beneficiary’s coinsurance is now calculated based on the inflation-adjusted price, not the drug’s higher market price. This means that if a manufacturer raises a drug’s price by 10% but inflation is only 3%, seniors will only pay their 20% coinsurance on the 3% increase. This directly and immediately lowers out-of-pocket costs for beneficiaries receiving expensive infused or injected drugs in a clinical setting, a powerful and direct consumer protection that many analysts did not expect to be implemented so forcefully.

Frequently Asked Questions

When do the first negotiated drug prices take effect? The first negotiated prices for the initial 10 selected drugs will become effective on January 1, 2026.

Do these changes apply to Medicare Advantage plans? Yes. All of these changes, including the price negotiations, the $2,000 out-of-pocket cap, and the inflation rebates, apply to prescription drug coverage whether you have a standalone Part D plan or a Medicare Advantage plan (MA-PD).

How will I know if a drug I take is subject to a new negotiated price? CMS will publicly announce the “Maximum Fair Prices” after the negotiation period ends. These new, lower prices will be reflected in your plan’s formulary and what you pay at the pharmacy starting in 2026.